BioPharmSignal logoBioPharmSignal

Biotech News

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Alkermes plc (ALKS)Alkermes plcClinical readout

— 26 Abstracts Accepted Demonstrate Alkermes’ Commitment to Advancing Understanding and Treatment of Narcolepsy and Idiopathic Hypersomnia — — Detailed Positive Results from Vibrance-2 Phase 2 Study of Alixorexton, an Orexin 2 Receptor Agonist, in Patients With Narcolepsy Type 2 to be Shared in

Related news

ALKSAlkermes plc2026-06-17 20:15 EST

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

ALKSAlkermes plc2026-07-13 11:00 EST

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

ANNXAnnexon, Inc.2026-07-14 20:05 EST

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

HRMYHarmony Biosciences2026-08-04 11:30 EST

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

KTTAPasithea Therapeutics2026-06-30 11:00 EST

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

TSHATaysha Gene Therapies2026-06-22 12:00 EST

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DNLIDenali Therapeutics2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-07-28 11:00 EST

Alkermes plc Reports Second Quarter 2026 Financial Results

ALKSAlkermes plc2026-07-14 20:00 EST

Alkermes to Report Second Quarter Financial Results on July 28, 2026

ALKSAlkermes plc2026-07-13 11:00 EST

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

ALKSAlkermes plc2026-06-17 20:15 EST

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

ALKSAlkermes plc2026-06-15 11:00 EST

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Stock data

Close
48.37 USD
Market cap
6.89B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States